Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Gemtuzumab ozogamicin is a CD33-directed antibody and DNA-binding agent. It targets CD33, a protein found on the surface of myeloid leukemia cells, and delivers a cytotoxic agent (ozogamicin) to these cells, leading to cell death.
## Primary Indications
* Treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive induction chemotherapy.
* Treatment of relapsed or refractory AML in adult patients.
## Adult Dosing
**Newly Diagnosed AML (in combination with other chemotherapy):**
* **Cycle 1:** 3 mg/m² on days 1, 4, and 7.
* **Cycle 2 (if chemotherapy is given):** 3 mg/m² on day 1.
* **Maximum cumulative dose:** 13.8 mg/m² over the course of treatment.
**Relapsed or Refractory AML:**
* **First course:** 3 mg/m² on day 1. If tolerated, subsequent doses of 3 mg/m² on days 4 and 7.
* **Subsequent courses (if disease has not progressed and patient is tolerating treatment):** 3 mg/m² every 2 to 4 weeks.
* **Maximum cumulative dose:** 13.8 mg/m² over the course of treatment.
*Note: Exact dosing may depend on specific clinical trial protocols or local institutional guidelines.*
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients.
## Dose Adjustments
* **Hepatotoxicity:** If veno-occlusive liver disease (VOD)/sinusoidal obstruction syndrome (SOS) occurs, discontinue treatment. For other hepatic toxicities, dose reductions or discontinuation may be necessary based on severity.
* **Myelosuppression:** Management of myelosuppression should be guided by standard clinical practice, including the use of growth factors and transfusions. Dose delays or reductions may be considered.
## Contraindications
* None specifically listed for gemtuzumab ozogamicin itself, but it should be used cautiously in patients with severe hepatic impairment.
## Adverse Effects
* **Common:** Febrile neutropenia, nausea, vomiting, diarrhea, mucositis, headache, rash, fatigue, anemia, thrombocytopenia, leukopenia, elevated liver enzymes (AST, ALT, bilirubin), VOD/SOS.
* **Serious:** Veno-occlusive liver disease (VOD)/sinusoidal obstruction syndrome (SOS), severe myelosuppression, infusion-related reactions, tumor lysis syndrome, embryo-fetal toxicity.
## Key Drug Interactions
* **Other myelosuppressive agents:** Increased risk of severe myelosuppression.
* **Hepatotoxic agents:** Increased risk of hepatotoxicity.
## Monitoring
* **Complete Blood Counts (CBC) with differential and platelet count:** Prior to each dose, weekly, and as clinically indicated.
* **Liver Function Tests (LFTs):** Prior to each dose and as clinically indicated. Monitor closely for signs of VOD/SOS.
* **Renal Function:** Monitor as clinically indicated.
* **Infusion-related reactions:** Monitor closely during and after infusion.
* **Signs and symptoms of VOD/SOS:** Monitor closely throughout treatment.
## Clinical Pearls
* Gemtuzumab ozogamicin carries a Black Box Warning for hepatotoxicity, including VOD/SOS, which can be fatal. Risk factors include prior stem cell transplant, prior or concurrent therapy with potent myelosuppressive agents, and severe baseline hepatic impairment.
* Administer premedication (e.g., acetaminophen, antihistamine) as per institutional protocol to reduce infusion-related reactions.
* Ensure patients are adequately hydrated and counsel on potential gastrointestinal toxicities.
* Due to the risk of embryo-fetal toxicity, patients of childbearing potential should be advised to use effective contraception.
***
**Disclaimer:** This information is intended for healthcare professionals and is a summary. It is essential to consult the most current prescribing information and relevant literature for complete details and to guide clinical decision-making. Dosing and management may vary based on individual patient factors and institutional protocols.
